Evidence map›Paper›PMID 31186695›Full record

ArticleOncology letters2019

Expression of miRNA-146b-5p in patients with thyroid cancer in combination with Hashimoto's disease and its clinical significance.

Ninglei Li, Xiaolong Liu, Luzhe Han, Rui Zhou, Jian Yan, Guoxiang Zhao, Lixin Liu

Abstract read
In one paragraph

Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. BRAFBiomedicines · 2022
    Article
  6. Hatching is modulated by microRNA-378a-3p derived from extracellular vesicles secreted by blastocysts.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ninglei LiDepartment of General Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong 510000, P.R. China.
Xiaolong LiuDepartment of General Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong 510000, P.R. China.
Luzhe HanDepartment of General Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong 510000, P.R. China.
Rui ZhouDepartment of General Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong 510000, P.R. China.
Jian YanDepartment of General Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong 510000, P.R. China.
Guoxiang ZhaoDepartment of General Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong 510000, P.R. China.
Lixin LiuDepartment of General Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong 510000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The expression level of microRNA (miRNA)-146b in patients with thyroid carcinoma (TC) in combination with Hashimoto's thyroditis (HT) was evaluated to analyze the clinical significance. Eighty-seven patients who underwent thyroid surgery in The Third Affiliated Hospital of Southern Medical University from March 2010 to February 2013 were enrolled. Of the patients, 37 were diagnosed with TC (group A), and 50 were diagnosed with TC in combination with HT (group B). Forty patients were diagnosed with HT (group C). The expression levels of miRNA-146b-5p in cancer tissue and paracancerous tissue of patients in the two groups were measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Correlation between the miRNA-146b-5p levels and the clinicopathological characteristics of patients with combined TC and HT were evaluated. According to the expression of miRNA-146b-5p, patients in group B were separated into the high and low expression groups to observe the five-year cancer recurrence rate. There was no significant difference in miRNA-146b-5p expression between the papillary carcinoma group, the follicular carcinoma group and the medullary carcinoma group (P>0.05). The miRNA-146b-5p expression in the lesion tissue of group B was significantly higher than that of groups A and C, while the miRNA-146b-5p expression in the lesion tissue of group A was significantly higher than that of group C (P<0.05), and the lesion tissue of the three groups was higher than that of the corresponding parastatal tissue (P<0.05). The miRNA-146b-5p expression level was associated with tumor size, lymph node metastasis and TNM stage (P<0.05), while not associated with sex, age, lesion multiplicity, smoking history, diabetes history and pathological type in group B (P>0.05). The non-recurrence rate of group B high expression subgroup was lower than that of group B low expression subgroup (P=0.045). High expression of miRNA-146b-5p was found in the cancer tissues of patients with combined TC and HT. The expression level of miRNA-146b-5p was associated with tumor size, lymph node metastasis and TNM stage. It is a potential prognostic indicator for patients with combined TC and HT.

Indexed as

clinicopathological characteristicsHashimoto's diseasemiRNA-146b-5pprognosisthyroid carcinoma

Identifiers

PMID31186695
PMCPMC6507475

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.